In the present study, we further examined whether ALWPs can affect AD pathology (including Aβ plaque and tau hyperphosphorylation) and found that oral administration of ALWPs significantly decreased amyloid plaque number as well as tau hyperphosphorylation in the cortex and hippocampus of 5x FAD mice, a model of AD. The gene discussed is MAPT; the disease is amyloidosis.